The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
The purpose of this study is to assess the safety, tolerability, and antitumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen.
Ibrutinib may impair natural killer cell cytotoxic activity, potentially through off-target inhibition of IL-2–inducible kinase (ITK), an in vitro study suggests.
The FDA has approved Revlimid (lenalidomide; Celgene) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
A second-generation anti-CD19 chimeric antigen receptor T-cell therapy showed clinical benefit and low toxicity in a phase 1 trial for B-cell lymphoma.
The detection of extranodal, soft tissue, bone, and spleen involvement at baseline predicted poor survival outcomes in patients with untreated follicular lymphoma.
For patients with advanced-stage Hodgkin lymphoma (HL) with large tumors, limited evidence suggests that consolidation radiotherapy (RT) after chemotherapy may prolong progression-free survival.
Results of a retrospective study of the treatment patterns and outcomes of a cohort of children and young adults with relapsed/refractory Hodgkin lymphoma showed high 5-year rates of freedom from local failure and overall survival (OS) in patients receiving moderate-dose salvage radiation therapy.
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
